3 Drugs Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 16,551 as of Wednesday, April 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,684 issues advancing vs. 1,250 declining with 198 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include Dr. Reddy Laboratories ( RDY), up 2.7%, AbbVie ( ABBV), up 1.5%, Pfizer ( PFE), up 0.8%, Shire ( SHPG), up 0.7% and Novo Nordisk A/S ( NVO), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Mylan ( MYL) is one of the companies pushing the Drugs industry higher today. As of noon trading, Mylan is up $1.19 (2.4%) to $50.50 on average volume. Thus far, 2.8 million shares of Mylan exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $49.61-$50.98 after having opened the day at $49.68 as compared to the previous trading day's close of $49.31.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $18.2 billion and is part of the health care sector. Shares are up 12.5% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $1.16 (0.9%) to $124.90 on light volume. Thus far, 933,530 shares of Allergan exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $123.92-$125.20 after having opened the day at $124.94 as compared to the previous trading day's close of $123.74.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $37.1 billion and is part of the health care sector. Shares are up 11.7% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Allergan a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.81 (1.5%) to $53.88 on heavy volume. Thus far, 6.5 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7.2 million shares. The stock has ranged in price between $53.05-$54.70 after having opened the day at $53.08 as compared to the previous trading day's close of $53.07.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $50.0 billion and is part of the health care sector. Shares are up 32.4% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Stocks Search for Direction as Trump Comments Lead to Worries Over China Talks

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

General Electric's Stock Gets Routed as CEO Flannery Flubs Presentation

Italy's President Gives Mandate For Anti-European Government in Rome

Italy's President Gives Mandate For Anti-European Government in Rome